Rheumatology Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drug Class (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Uric Acid Drugs, Disease Modifying Anti-Rheumatic Drugs (DMARDs)); Disease Indication (Rheumatoid Arthritis, Osteoarthritis, Gout, Psoriatic Arthritis, Ankylosing Spondylitis); Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)

Report Code: TIPRE00021202 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!
MARKET INTRODUCTION

Rheumatology indicates the discipline of internal medicine, including the diagnosis and treatment of rheumatic diseases. Rheumatic diseases are described as the inflammation that affects joints, tendons, bones, ligaments, and sometimes organs. These conditions are also known as musculoskeletal disease, causing deformity, severe pain, and morbidity. The treatment leads to be very costly. Various types of rheumatic diseases with several symptoms are seen all over the world among all age groups.

MARKET DYNAMICS

The rheumatology market is driving due to growth in awareness regarding the early diagnosis and treatment of rheumatology disease symptoms and the increasing use of disease-modifying anti-rheumatic drugs (DMARD's) for treatment of the respective condition. However, the high R&D cost involved in product development will hamper its growth. Moreover, rise in the rate of launches of novel biologics drugs, increasing approvals, and growing penetration of generic medicines is expected to provide opportunities in the global rheumatology market.

MARKET SCOPE

The "Rheumatology Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of Rheumatology market with detailed market segmentation by drug class, disease indication, and distribution channel. The rheumatology market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in rheumatology market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The rheumatology market is segmented based on drug class, disease indication, and distribution channel. Based on drug class, the market is segmented into nonsteroidal anti-inflammatory drugs (NSAID's), corticosteroids, uric acid drugs, disease modifying anti-rheumatic drugs (DMARD's). Based on disease indication, the market is segmented as rheumatoid arthritis, osteoarthritis, gout, psoriatic arthritis, ankylosing spondylitis. Based on distribution channel, the market is segmented as hospital pharmacy, retail pharmacy, online pharmacy.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the rheumatology market based on various segments. It also provides market size and forecast estimates from year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The rheumatology market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Rheumatology market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social, and technological factors effecting the rheumatology market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the rheumatology market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from rheumatology market are anticipated to have lucrative growth opportunities in the future with the rising demand for rheumatology in the global market. Below mentioned is the list of few companies engaged in the rheumatology market.

The report also includes the profiles of key players in rheumatology market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •   AbbVie Inc.
  •   Bristol-Myers Squibb Company
  •   Pfizer Inc.
  •   Merck & Co., Inc.
  •   Amgen Inc.
  •   Novartis AG
  •   Janssen Pharmaceuticals, Inc.
  •   Sanofi
  •   Genentech, Inc.
  •   Takeda Pharmaceutical Company Limited

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Rheumatology Market - By Drug Class
1.3.2 Rheumatology Market - By Disease Indication
1.3.3 Rheumatology Market - By Distribution Channel
1.3.4 Rheumatology Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. RHEUMATOLOGY MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. RHEUMATOLOGY MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. RHEUMATOLOGY MARKET - GLOBAL MARKET ANALYSIS
6.1. RHEUMATOLOGY - GLOBAL MARKET OVERVIEW
6.2. RHEUMATOLOGY - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. RHEUMATOLOGY MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAID'S)
7.3.1. Overview
7.3.2. Nonsteroidal Anti-Inflammatory Drugs (NSAID's) Market Forecast and Analysis
7.4. CORTICOSTEROIDS
7.4.1. Overview
7.4.2. Corticosteroids Market Forecast and Analysis
7.5. URIC ACID DRUGS
7.5.1. Overview
7.5.2. Uric Acid Drugs Market Forecast and Analysis
7.6. DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (DMARD'S)
7.6.1. Overview
7.6.2. Disease Modifying Anti-Rheumatic Drugs (DMARD's) Market Forecast and Analysis
8. RHEUMATOLOGY MARKET - REVENUE AND FORECASTS TO 2028 - DISEASE INDICATION
8.1. OVERVIEW
8.2. DISEASE INDICATION MARKET FORECASTS AND ANALYSIS
8.3. RHEUMATOID ARTHRITIS
8.3.1. Overview
8.3.2. Rheumatoid Arthritis Market Forecast and Analysis
8.4. OSTEOARTHRITIS
8.4.1. Overview
8.4.2. Osteoarthritis Market Forecast and Analysis
8.5. GOUT
8.5.1. Overview
8.5.2. Gout Market Forecast and Analysis
8.6. PSORIATIC ARTHRITIS
8.6.1. Overview
8.6.2. Psoriatic Arthritis Market Forecast and Analysis
8.7. ANKYLOSING SPONDYLITIS
8.7.1. Overview
8.7.2. Ankylosing Spondylitis Market Forecast and Analysis
9. RHEUMATOLOGY MARKET - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
9.1. OVERVIEW
9.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
9.3. HOSPITAL PHARMACY
9.3.1. Overview
9.3.2. Hospital Pharmacy Market Forecast and Analysis
9.4. RETAIL PHARMACY
9.4.1. Overview
9.4.2. Retail Pharmacy Market Forecast and Analysis
9.5. ONLINE PHARMACY
9.5.1. Overview
9.5.2. Online Pharmacy Market Forecast and Analysis
10. RHEUMATOLOGY MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Rheumatology Market Overview
10.1.2 North America Rheumatology Market Forecasts and Analysis
10.1.3 North America Rheumatology Market Forecasts and Analysis - By Drug Class
10.1.4 North America Rheumatology Market Forecasts and Analysis - By Disease Indication
10.1.5 North America Rheumatology Market Forecasts and Analysis - By Distribution Channel
10.1.6 North America Rheumatology Market Forecasts and Analysis - By Countries
10.1.6.1 United States Rheumatology Market
10.1.6.1.1 United States Rheumatology Market by Drug Class
10.1.6.1.2 United States Rheumatology Market by Disease Indication
10.1.6.1.3 United States Rheumatology Market by Distribution Channel
10.1.6.2 Canada Rheumatology Market
10.1.6.2.1 Canada Rheumatology Market by Drug Class
10.1.6.2.2 Canada Rheumatology Market by Disease Indication
10.1.6.2.3 Canada Rheumatology Market by Distribution Channel
10.1.6.3 Mexico Rheumatology Market
10.1.6.3.1 Mexico Rheumatology Market by Drug Class
10.1.6.3.2 Mexico Rheumatology Market by Disease Indication
10.1.6.3.3 Mexico Rheumatology Market by Distribution Channel
10.2. EUROPE
10.2.1 Europe Rheumatology Market Overview
10.2.2 Europe Rheumatology Market Forecasts and Analysis
10.2.3 Europe Rheumatology Market Forecasts and Analysis - By Drug Class
10.2.4 Europe Rheumatology Market Forecasts and Analysis - By Disease Indication
10.2.5 Europe Rheumatology Market Forecasts and Analysis - By Distribution Channel
10.2.6 Europe Rheumatology Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Rheumatology Market
10.2.6.1.1 Germany Rheumatology Market by Drug Class
10.2.6.1.2 Germany Rheumatology Market by Disease Indication
10.2.6.1.3 Germany Rheumatology Market by Distribution Channel
10.2.6.2 France Rheumatology Market
10.2.6.2.1 France Rheumatology Market by Drug Class
10.2.6.2.2 France Rheumatology Market by Disease Indication
10.2.6.2.3 France Rheumatology Market by Distribution Channel
10.2.6.3 Italy Rheumatology Market
10.2.6.3.1 Italy Rheumatology Market by Drug Class
10.2.6.3.2 Italy Rheumatology Market by Disease Indication
10.2.6.3.3 Italy Rheumatology Market by Distribution Channel
10.2.6.4 Spain Rheumatology Market
10.2.6.4.1 Spain Rheumatology Market by Drug Class
10.2.6.4.2 Spain Rheumatology Market by Disease Indication
10.2.6.4.3 Spain Rheumatology Market by Distribution Channel
10.2.6.5 United Kingdom Rheumatology Market
10.2.6.5.1 United Kingdom Rheumatology Market by Drug Class
10.2.6.5.2 United Kingdom Rheumatology Market by Disease Indication
10.2.6.5.3 United Kingdom Rheumatology Market by Distribution Channel
10.2.6.6 Rest of Europe Rheumatology Market
10.2.6.6.1 Rest of Europe Rheumatology Market by Drug Class
10.2.6.6.2 Rest of Europe Rheumatology Market by Disease Indication
10.2.6.6.3 Rest of Europe Rheumatology Market by Distribution Channel
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Rheumatology Market Overview
10.3.2 Asia-Pacific Rheumatology Market Forecasts and Analysis
10.3.3 Asia-Pacific Rheumatology Market Forecasts and Analysis - By Drug Class
10.3.4 Asia-Pacific Rheumatology Market Forecasts and Analysis - By Disease Indication
10.3.5 Asia-Pacific Rheumatology Market Forecasts and Analysis - By Distribution Channel
10.3.6 Asia-Pacific Rheumatology Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Rheumatology Market
10.3.6.1.1 Australia Rheumatology Market by Drug Class
10.3.6.1.2 Australia Rheumatology Market by Disease Indication
10.3.6.1.3 Australia Rheumatology Market by Distribution Channel
10.3.6.2 China Rheumatology Market
10.3.6.2.1 China Rheumatology Market by Drug Class
10.3.6.2.2 China Rheumatology Market by Disease Indication
10.3.6.2.3 China Rheumatology Market by Distribution Channel
10.3.6.3 India Rheumatology Market
10.3.6.3.1 India Rheumatology Market by Drug Class
10.3.6.3.2 India Rheumatology Market by Disease Indication
10.3.6.3.3 India Rheumatology Market by Distribution Channel
10.3.6.4 Japan Rheumatology Market
10.3.6.4.1 Japan Rheumatology Market by Drug Class
10.3.6.4.2 Japan Rheumatology Market by Disease Indication
10.3.6.4.3 Japan Rheumatology Market by Distribution Channel
10.3.6.5 South Korea Rheumatology Market
10.3.6.5.1 South Korea Rheumatology Market by Drug Class
10.3.6.5.2 South Korea Rheumatology Market by Disease Indication
10.3.6.5.3 South Korea Rheumatology Market by Distribution Channel
10.3.6.6 Rest of Asia-Pacific Rheumatology Market
10.3.6.6.1 Rest of Asia-Pacific Rheumatology Market by Drug Class
10.3.6.6.2 Rest of Asia-Pacific Rheumatology Market by Disease Indication
10.3.6.6.3 Rest of Asia-Pacific Rheumatology Market by Distribution Channel
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Rheumatology Market Overview
10.4.2 Middle East and Africa Rheumatology Market Forecasts and Analysis
10.4.3 Middle East and Africa Rheumatology Market Forecasts and Analysis - By Drug Class
10.4.4 Middle East and Africa Rheumatology Market Forecasts and Analysis - By Disease Indication
10.4.5 Middle East and Africa Rheumatology Market Forecasts and Analysis - By Distribution Channel
10.4.6 Middle East and Africa Rheumatology Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Rheumatology Market
10.4.6.1.1 South Africa Rheumatology Market by Drug Class
10.4.6.1.2 South Africa Rheumatology Market by Disease Indication
10.4.6.1.3 South Africa Rheumatology Market by Distribution Channel
10.4.6.2 Saudi Arabia Rheumatology Market
10.4.6.2.1 Saudi Arabia Rheumatology Market by Drug Class
10.4.6.2.2 Saudi Arabia Rheumatology Market by Disease Indication
10.4.6.2.3 Saudi Arabia Rheumatology Market by Distribution Channel
10.4.6.3 U.A.E Rheumatology Market
10.4.6.3.1 U.A.E Rheumatology Market by Drug Class
10.4.6.3.2 U.A.E Rheumatology Market by Disease Indication
10.4.6.3.3 U.A.E Rheumatology Market by Distribution Channel
10.4.6.4 Rest of Middle East and Africa Rheumatology Market
10.4.6.4.1 Rest of Middle East and Africa Rheumatology Market by Drug Class
10.4.6.4.2 Rest of Middle East and Africa Rheumatology Market by Disease Indication
10.4.6.4.3 Rest of Middle East and Africa Rheumatology Market by Distribution Channel
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Rheumatology Market Overview
10.5.2 South and Central America Rheumatology Market Forecasts and Analysis
10.5.3 South and Central America Rheumatology Market Forecasts and Analysis - By Drug Class
10.5.4 South and Central America Rheumatology Market Forecasts and Analysis - By Disease Indication
10.5.5 South and Central America Rheumatology Market Forecasts and Analysis - By Distribution Channel
10.5.6 South and Central America Rheumatology Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Rheumatology Market
10.5.6.1.1 Brazil Rheumatology Market by Drug Class
10.5.6.1.2 Brazil Rheumatology Market by Disease Indication
10.5.6.1.3 Brazil Rheumatology Market by Distribution Channel
10.5.6.2 Argentina Rheumatology Market
10.5.6.2.1 Argentina Rheumatology Market by Drug Class
10.5.6.2.2 Argentina Rheumatology Market by Disease Indication
10.5.6.2.3 Argentina Rheumatology Market by Distribution Channel
10.5.6.3 Rest of South and Central America Rheumatology Market
10.5.6.3.1 Rest of South and Central America Rheumatology Market by Drug Class
10.5.6.3.2 Rest of South and Central America Rheumatology Market by Disease Indication
10.5.6.3.3 Rest of South and Central America Rheumatology Market by Distribution Channel
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL RHEUMATOLOGY MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Middle East and Africa
11.5 South and Central America
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. RHEUMATOLOGY MARKET, KEY COMPANY PROFILES
13.1. ABBVIE INC.
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. BRISTOL-MYERS SQUIBB COMPANY
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. PFIZER INC.
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. MERCK AND CO., INC.
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. AMGEN INC.
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. NOVARTIS AG
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. JANSSEN PHARMACEUTICALS, INC.
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. SANOFI
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. GENENTECH, INC.
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. TAKEDA PHARMACEUTICAL COMPANY LIMITED
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
The List of Companies

1. AbbVie Inc.
2. Bristol-Myers Squibb Company
3. Pfizer Inc.
4. Merck & Co., Inc.
5. Amgen Inc.
6. Novartis AG
7. Janssen Pharmaceuticals, Inc.
8. Sanofi
9. Genentech, Inc.
10. Takeda Pharmaceutical Company Limited
11. Johnson & Johnson Private Limited
12. F. Hoffmann-La Roche Ltd
13. UCB S.A.
14. Gilead Sciences, Inc.
15. Boehringer Ingelheim International GmbH
16. Regeneron Pharmaceuticals Inc.
17. Eli Lilly and Company
18. Qiagen NV
19. Euro Diagnostica AB
20. Antibodies Inc.
TIPRE00021202
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking